That puts the research-based sector in a difficult spot. Will it pay, in explicit savings drawn from the existing pool of funded medicines and technologies, for the privilege of faster, allegedly lighter-touch assessment pathways for a handful of new 'unicorn' therapies? Is it worth it? …
If the demand is to pay for reform, are these reforms really worth paying for?
May 18, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Ex-Novartis leader joins the board of emerging nuclear medicine company
July 17, 2026 - - Latest News -
It doesn't always feel like it, but make no mistake, this is what winning looks like
July 17, 2026 - - Latest News -
Telix opens Australia's first integrated radiopharmaceutical facility in Melbourne
July 16, 2026 - - Latest News -
A single payer system in which the worst kind of inequity is the only one permitted
July 16, 2026 - - Latest News -
Organon and Samsung Bioepis expand partnership to broaden biosimilar access in Australia
July 16, 2026 - - Latest News -
Arthritis Australia unveils new grants and identity as research breakthroughs loom
July 16, 2026 - - Latest News -
Algorae names Nasdaq pharmaceutical chairman to strengthen board
July 15, 2026 - - Australian Biotech